
Supplementary material

Supplementary Figure 1. The analytic sample within the COVID-19 National Resilience Cohort.



Supplementary Table 1. Mean and median scores on PHQ-9, GAD-7, and PC-PTSD-5 among individuals with and without a recent COVID-19 diagnosis.

	Mean sc	Mean scores		Median scores		Adj. P- value
	Individuals not diagnosed with COVID-19	Individuals diagnosed with COVID-19	Individuals not diagnosed with COVID-19	Individuals diagnosed with COVID-19		
Depression	5.07	6.11	4	5	<.001	<.001
Anxiety	4.12	4.52	3	4	.07	.08
PTSD	1.72	1.90	2	2	.007	<.001

^a Adjusted for age (continuous variable), gender (male, female, or other), educational level (compulsory education, high school/trade school/other education, bachelor's degree/diploma certificate, or master's/Ph.D. degree), income (continuous variable), current smoking (yes or no), previous diagnosis of a psychiatric disorder (yes or no), number of previously diagnosed somatic diseases (0, 1, or ≥ 2), and timing of responding to the baseline questionnaire (April 24-30, May 1-7, May 8-23, or May 24-July 22).

Supplementary Table 2. The prevalence, crude and multivariable adjusted relative risks and absolute differences in symptoms of depression (PHQ-9), anxiety (GAD-7) and PTSD (PC-PTSD-5) surpassing screening thresholds among individuals with and without a confirmed diagnosis of COVID-19. The data are presented with stratification of all covariates used in the multivariable adjusted models along with the p-values for the effect modification.

	No.	(%)					_
	Individuals not diagnosed with COVID-19	Individuals diagnosed with COVID-19	cRR (95% CI)	aRR (95% CI)ª	Absolute difference Crude %	Absolute difference Adjusted ^a %	P-value for effect modification
Depression	2992 (16.2)	75 (22.1)	1.36 (1.11 to 1.67)	1.48 (1.20 to 1.82)	5.9	8.4	-
Female	2421 (18.8)	56 (24.8)	1.32 (1.05 to 1.66)	1.43 (1.13 to 1.81)	6.0	8.1	0.110
Male	559 (10.0)	17 (15.2)	1.52 (0.97 to 2.37)	1.54 (0.96 to 2.47)	5.2	7.2	
18-39 years	954 (33.3)	23 (27.1)	0.81 (0.57 to 1.16)	0.94 (0.65 to 1.36)	-6.2	-1.8	0.025
40-59 years	1367 (16.8)	40 (22.3)	1.33 (1.01 to 1.75)	1.72 (1.31 to 2.27)	5.5	14.7	
≥60 years	671 (8.9)	12 (15.8)	1.77 (1.05 to 2.98)	2.57 (1.52 to 4.36)	6.9	21.8	
Compulsory education	540 (21.5)	6 (23.1)	1.07 (0.53-2.17)	1.24 (0.61-2.53)	1.6	4.7	<.001
Upper secondary, vocational or other education	996 (17.7)	15 (14.7)	0.83 (0.52-1.33)	0.83 (0.51-1.33)	-2.9	-2.5	
Bachelor's degree or diploma certificate	935 (15.7)	30 (24.2)	1.54 (1.12-2.12)	1.56 (1.16-2.08)	8.5	10.2	
Master's or Ph.D. degree	521 (11.9)	24 (27.3)	2.28 (1.61-3.24)	2.95 (2.03-4.29)	15.3	34.5	
Low income	966 (29.8)	15 (31.3)	1.05 (0.69-1.60)	0.97 (0.61-1.55)	1.5	-0.8	0.059
Low-medium income	956 (18.1)	21 (25.3)	1.40 (0.96-2.04)	1.36 (0.97-1.89)	7.2	8.3	
Medium income	637 (13.4)	18 (23.4)	1.75 (1.16-2.64)	1.66 (1.09-2.55)	10.0	12.6	
Medium-high income	316 (9.3)	13 (15.1)	1.63 (0.98-2.72)	2.04 (1.24-3.35)	5.8	13.1	
High income	117 (6.6)	8 (17.3)	2.64 (1.37-5.08)	2.90 (1.56-5.37)	10.8	15.3	

Not current smoker	2351 (14.5)	71 (22.0)	1.52 (1.23-1.87)	1.53 (1.23-1.89)	7.6	8.0	0.234
Current smoker	641 (28.3)	4 (22.2)	0.79 (0.33-1.87)	0.91 (0.36-2.33)	-6.1	-1.6	
No previous diagnosis of psychiatric disorder	1053 (8.0)	38 (14.6)	1.83 (1.36-2.47)	1.55 (1.13-2.12)	6.6	5.6	0.176
Previous diagnosis of psychiatric disorder	1939 (37.0)	37 (46.8)	1.27 (1.00-1.61)	1.36 (1.04-1.77)	9.9	13.6	
No previously diagnosed somatic diseases	1776 (16.2)	54 (22.4)	1.38 (1.09-1.75)	1.52 (1.19-1.95)	6.2	7.7	0.923
1 previously diagnosed somatic disease	785 (14.6)	17 (20.7)	1.42 (0.92-2.18)	1.38 (0.91-2.10)	6.1	6.2	
≥ 2 previously diagnosed somatic diseases	431 (19.8)	4 (23.5)	1.19 (0.50-2.81)	1.88 (0.70-5.06)	3.7	14.7	
Response date: April 24-May 7	2206 (18.3)	45 (27.4)	1.50 (1.16-1.93)	1.62 (1.24-2.11)	9.1	12.6	0.531
Response date: May 8-July 22	786 (12.2)	30 (17.0)	1.40 (1.00-1.95)	1.24 (0.89-1.71)	4.9	3.2	
Anxiety	2120 (11.3)	45 (13.1)	1.16 (0.88 to 1.53)	1.24 (0.93 to 1.64)	1.8	2.6	
Female	1759 (13.4)	34 (14.8)	1.11 (0.81 to 1.51)	1.17 (0.84 to 1.62)	1.4	2.2	0.007
Male	353 (6.2)	10 (8.9)	1.43 (0.78 to 2.60)	1.39 (0.76 to 2.54)	2.6	3.0	
18-39 years	770 (26.2)	13 (14.9)	0.57 (0.34 to 0.95)	0.61 (0.36 to 1.04)	-11.3	-9.3	0.049
40-59 years	951 (11.5)	27 (14.7)	1.28 (0.90 to 1.82)	1.70 (1.20 to 2.41)	3.2	10.5	
≥60 years	399 (5.2)	5 (6.9)	1.31 (0.56 to 3.06)	2.13 (0.91 to 5.00)	1.7	7.5	
Compulsory education	378 (14.7)	2 (8.0)	0.54 (0.14-2.06)	0.75 (0.21-2.69)	-6.7	-2.7	0.009
Upper secondary, vocational or other education	690 (12.0)	11 (10.5)	0.87 (0.50-1.54)	0.84 (0.48-1.48)	-1.5	-1.4	
Bachelor's degree or diploma certificate	658 (10.9)	17 (13.4)	1.23 (0.79-1.93)	1.18 (0.74-1.86)	2.5	2.0	
Master's or Ph.D. degree	394 (8.9)	15 (17.2)	1.94 (1.21-3.11)	2.47 (1.53-3.99)	8.4	19.6	
Low income	719 (21.6)	6 (12.5)	0.58 (0.27-1.23)	0.52 (0.24-1.12)	-9.1	-8.9	0.082
Low-medium income	657 (12.2)	17 (19.8)	1.62 (1.06-2.50)	1.44 (0.95-2.20)	7.6	6.6	

Medium income	432 (8.9)	11 (14.5)	1.62 (0.93-2.82)	1.58 (0.89-2.81)	5.5	6.1	
Medium-high income	223 (6.5)	9 (10.3)	1.60 (0.85-3.01)	2.05 (1.03-4.09)	3.9	8.0	
High income	89 (5.0)	2 (4.3)	0.86 (0.22-3.38)	0.97 (0.25-3.73)	-0.7	-0.1	
Not current smoker	1641 (10.0)	43 (13.2)	1.33 (1.00-1.76)	1.31 (0.98-1.76)	3.3	3.0	0.193
Current smoker	479 (20.6)	2 (10.5)	0.51 (0.14-1.90)	0.51 (0.13-1.98)	-10.1	-6.1	
No previous diagnosis of psychiatric disorder	709 (5.3)	24 (9.2)	1.73 (1.18-2.55)	1.46 (0.97-2.19)	3.9	2.5	0.130
Previous diagnosis of psychiatric disorder	1411 (26.1)	21 (25.6)	0.98 (0.68-1.42)	1.03 (0.70-1.52)	-0.5	0.8	
No previously diagnosed somatic diseases	1320 (11.9)	34 (13.9)	1.17 (0.85-1.60)	1.22 (0.88-1.71)	2.0	2.2	0.651
1 previously diagnosed somatic disease	519 (9.5)	10 (12.3)	1.30 (0.72-2.34)	1.31 (0.71-2.41)	2.9	3.0	
≥ 2 previously diagnosed somatic diseases	281 (12.6)	1 (5.6)	0.44 (0.07-2.97)	0.75 (0.22-2.52)	-7.0	-2.7	
Response date: April 24-May 7	1594 (13.0)	28 (16.7)	1.28 (0.91-1.80)	1.37 (0.97-1.94)	3.7	4.7	0.622
Response date: May 8-July 22	526 (8.0)	17 (9.7)	1.21 (0.76-1.91)	0.93 (0.57-1.52)	1.7	-0.6	
PTSD	2699 (15.6)	59 (19.5)	1.25 (0.99 to 1.57)	1.38 (1.09 to 1.75)	3.9	7.2	
Female	2198 (18.6)	46 (22.7)	1.22 (0.94 to 1.58)	1.32 (1.02 to 1.71)	4.1	6.7	<.001
Male	493 (9.1)	12 (12.1)	1.33 (0.78 to 2.27)	1.60 (0.92 to 2.77)	3.0	7.1	
18-39 years	597 (24.2)	11 (15.3)	0.63 (0.37 to 1.09)	0.77 (0.45 to 1.32)	-8.9	-6.2	0.003
40-59 years	1268 (16.7)	31 (19.3)	1.15 (0.84 to 1.59)	1.36 (0.99 to 1.88)	2.6	7.8	
≥60 years	834 (11.6)	17 (24.3)	2.09 (1.38 to 3.18)	2.67 (1.78 to 4.01)	12.7	27.9	
Compulsory education	367 (16.1)	7 (33.3)	2.08 (1.13-3.83)	2.41 (1.19-4.89)	17.2	24.8	0.239
Upper secondary, vocational or other education	809 (15.5)	20 (21.1)	1.36 (0.92-2.02)	1.44 (0.96-2.18)	5.6	9.1	
Bachelor's degree or diploma certificate	912 (16.4)	23 (21.1)	1.29 (0.89-1.86)	1.34 (0.93-1.94)	4.7	4.8	

Master's or Ph.D. degree	611 (14.7)	9 (11.5)	0.79 (0.42-1.46)	1.01 (0.55-1.84)	-3.1	0.2	
Low income	602 (21.0)	10 (22.7)	1.08 (0.62-1.87)	1.11 (0.64-1.93)	1.7	2.2	0.756
Low-medium income	773 (15.8)	17 (23.6)	1.49 (0.98-2.27)	1.53 (0.98-2.37)	7.8	9.9	
Medium income	726 (16.1)	12 (17.4)	1.08 (0.64-1.82)	1.16 (0.68-1.98)	1.3	2.8	
Medium-high income	403 (12.3)	14 (17.9)	1.46 (0.90-2.36)	1.77 (1.14-2.76)	5.6	16.4	
High income	195 (11.4)	6 (15.0)	1.32 (0.62-2.79)	1.53 (0.72-3.26)	3.6	6.7	
Not current smoker	2244 (14.7)	51 (17.9)	1.22 (0.95-1.56)	1.28 (0.99-1.65)	3.2	4.5	0.054
Current smoker	455 (22.6)	8 (44.4)	1.97 (1.17-3.32)	2.83 (1.57-5.10)	21.9	37.4	
No previous diagnosis of psychiatric disorder	1540 (12.2)	42 (17.6)	1.45 (1.10-1.92)	1.55 (1.17-2.06)	5.5	7.5	0.137
Previous diagnosis of psychiatric disorder	1159 (25.3)	17 (26.2)	1.04 (0.69-1.56)	1.11 (0.73-1.68)	0.9	3.0	
No previously diagnosed somatic diseases	1611 (15.8)	41 (19.4)	1.23 (0.93-1.62)	1.44 (1.09-1.90)	3.6	7.6	0.325
1 previously diagnosed somatic disease	751 (14.8)	12 (16.0)	1.08 (0.64-1.82)	1.11 (0.66-1.87)	1.2	1.8	
≥ 2 previously diagnosed somatic diseases	337 (16.7)	6 (35.3)	2.11 (1.10-4.04)	2.03 (0.94-4.40)	18.6	17.5	
Response date: April 24-May 7	1996 (18.1)	32 (22.5)	1.25 (0.92-1.70)	1.24 (0.91-1.70)	4.5	5.8	0.256
Response date: May 8-July 22	703 (11.4)	27 (16.8)	1.47 (1.04-2.09)	1.41 (0.99-2.01)	5.4	6.0	

^a Adjusted for age (continuous variable), gender (male, female, or other), educational level (compulsory education, high school/trade school/other education, bachelor's degree/diploma certificate, or master's/Ph.D. degree), income (continuous variable), current smoking (yes or no), previous diagnosis of a psychiatric disorder (yes or no), number of previously diagnosed somatic diseases (0, 1, or ≥ 2), and timing of responding to the baseline questionnaire (April 24-30, May 1-7, May 8-23, or May 24-July 22). Adjustments are not made for the variable that is being stratified by.

Supplementary Table 3. The prevalence, crude and multivariable adjusted relative risks and absolute differences in symptoms of depression (PHQ-9), anxiety (GAD-7) and PTSD (PC-PTSD-5) surpassing screening thresholds among individuals with and without a confirmed diagnosis of COVID-19 (*diagnosed at least two weeks before responding*).

	No. ((%)	-	-	_	
	Individuals not diagnosed	Individuals diagnosed with COVID-	- cRR (95% CI)	aRR (95% CI) ^a	Absolute difference	Absolute difference
	with COVID-19	19			Crude %	Adjusted ^a %
Depression	2992 (16.2)	73 (22.0)	1.36 (1.11 to 1.67)	1.49 (1.20 to 1.84)	5.8	8.6
Female	2421 (18.8)	55 (24.9)	1.32 (1.05 to 1.67)	1.45 (1.14 to 1.83)	6.1	8.4
Male	559 (10.0)	16 (14.7)	1.47 (0.93 to 2.33)	1.52 (0.93 to 2.49)	4.7	6.9
18-39 years	954 (33.3)	22 (26.8)	0.81 (0.56 to 1.16)	0.95 (0.65 to 1.39)	-6.5	-1.5
40-59 years	1367 (16.8)	39 (22.3)	1.32 (1.00 to 1.75)	1.72 (1.30 to 2.28)	5.5	14.7
≥60 years	671 (8.9)	12 (16.0)	1.79 (1.06 to 3.02)	2.59 (1.53 to 4.39)	7.1	22.0
Anxiety	2120 (11.3)	45 (13.1)	1.16 (0.88 to 1.54)	1.25 (0.94 to 1.67)	1.8	2.9
Female	1759 (13.4)	33 (14.7)	1.10 (0.80 to 1.51)	1.17 (0.84 to 1.64)	1.3	2.3
Male	353 (6.2)	10 (9.1)	1.46 (0.80 to 2.67)	1.46 (0.80 to 2.64)	2.9	3.5
18-39 years	770 (26.2)	13 (15.5)	0.59 (0.36 to 0.98)	0.64 (0.38 to 1.09)	-10.7	-8.6
40-59 years	951 (11.5)	26 (14.4)	1.26 (0.88 to 1.80)	1.68 (1.18 to 2.41)	2.9	10.2
≥60 years	399 (5.2)	5 (6.9)	1.32 (0.57 to 3.10)	2.15 (0.91 to 5.03)	1.7	7.5
PTSD	2699 (15.6)	56 (18.9)	1.21 (0.95 to 1.54)	1.35 (1.06 to 1.73)	3.3	6.7
Female	2198 (18.6)	43 (21.7)	1.17 (0.89 to 1.53)	1.27 (0.97 to 1.67)	3.1	5.7
Male	493 (9.1)	12 (12.4)	1.36 (0.79 to 2.32)	1.64 (0.95 to 2.83)	3.3	7.5
18-39 years	597 (24.2)	10 (14.3)	0.59 (0.33 to 1.05)	0.72 (0.41 to 1.28)	-9.9	-7.4
40-59 years	1268 (16.7)	29 (18.5)	1.11 (0.79 to 1.54)	1.31 (0.94 to 1.84)	1.8	6.7
≥60 years	834 (11.6)	17 (24.6)	2.12 (1.40 to 3.23)	2.70 (1.80 to 4.05)	13.0	28.3

^a Adjusted for age (continuous variable), gender (male, female, or other), educational level (compulsory education, high school/trade school/other education, bachelor's degree/diploma certificate, or master's/Ph.D. degree), income (continuous variable), current smoking (yes or no), previous diagnosis of a psychiatric disorder (yes or no), number of previously diagnosed somatic diseases (0, 1, or ≥ 2), and timing of responding to the baseline questionnaire (April 24-30, May 1-7, May 8-23, or May 24-July 22). Adjustments are not made for the variable that is being stratified by.

Supplementary Table 4. The prevalence, crude and multivariable adjusted relative risks and absolute differences in symptoms of depression (PHQ-9), anxiety (GAD-7) and PTSD (PC-PTSD-5) surpassing screening thresholds among individuals with and without a confirmed diagnosis of COVID-19 (using multiple imputation).

	No.	(%)	_	-		_
	Individuals not diagnosed with COVID-19	Individuals diagnosed with COVID-19	cRR (95% CI)	aRR (95% CI)ª	Absolute difference Crude %	Absolute difference Adjusted ^a %
Depression	3487 (17.0)	83 (22.3)	1.31 (1.08 to 1.59)	1.44 (1.18 to 1.75)	5.3	8.1
Female	2819 (19.7)	64 (25.6)	1.29 (1.05 to 1.61)	1.43 (1.14 to 1.78)	5.9	8.3
Male	655 (10.7)	17 (14.1)	1.32 (0.85 to 2.08)	1.35 (0.85 to 2.16)	3.4	4.6
18-39 years	1105 (35.2)	26 (28.9)	0.82 (0.59 to 1.14)	0.95 (0.67 to 1.33)	-6.3	-1.8
40-59 years	1565 (17.5)	445(22.5)	1.29 (0.99 to 1.68)	1.68 (1.29 to 2.18)	5.0	14.8
≥60 years	817 (9.7)	12 (14.8)	1.52 (0.90 to 2.58)	2.23 (1.31 to 3.78)	5.1	17.2
Anxiety	2328 (11.3)	45 (12.1)	1.06 (0.81 to 1.40)	1.15 (0.87 to 1.53)	0.8	1.8
Female	1940 (13.5)	34 (13.6)	1.01 (0.73 to 1.38)	1.08 (0.78 to 1.50)	0.1	1.0
Male	378 (6.2)	10 (8.3)	1.34 (0.73 to 2.45)	1.34 (0.74 to 2.43)	2.1	2.6
18-39 years	830 (26.5)	13 (14.4)	0.55 (0.33 to 0.91)	0.61 (0.36 to 1.03)	-12.1	-10.0
40-59 years	1037 (11.6)	27 (13.6)	1.18 (0.83 to 1.68)	1.57 (1.11 to 2.23)	2.0	9.0
≥60 years	461 (5.5)	5 (5.9)	1.08 (0.46 to 2.53)	1.69 (0.72 to 3.97)	0.4	4.6
PTSD	2915 (15.8)	62 (19.2)	1.22 (0.97 to 1.53)	1.36 (1.08 to 1.71)	3.4	6.7
Female	2375 (18.7)	48 (22.1)	1.18 (0.92 to 1.52)	1.29 (1.00 to 1.66)	3.4	6.1
Male	532 (9.2)	13 (12.4)	1.34 (0.80 to 2.25)	1.57 (0.93 to 2.67)	3.2	6.9
18-39 years	642 (24.5)	11 (14.9)	0.61 (0.35 to 1.05)	0.71 (0.41 to 1.22)	-9.6	-7.9
40-59 years	1360 (16.8)	33 (19.3)	1.15 (0.84 to 1.57)	1.37 (1.00 to 1.87)	2.5	7.9
≥60 years	913 (11.8)	18 (23.1)	1.96 (1.30 to 2.96)	2.47 (1.65 to 3.69)	11.3	23.9

^a Adjusted for age (continuous variable), gender (male, female, or other), educational level (compulsory education, high school/trade school/other education, bachelor's degree/diploma certificate, or master's/Ph.D. degree), income (continuous variable), current smoking (yes or no), previous diagnosis of a psychiatric disorder (yes or no), number of previously diagnosed somatic diseases (0, 1, or ≥ 2), and timing of responding to the baseline questionnaire (April 24-30, May 1-7, May 8-23, or May 24-July 22). Adjustments are not made for the variable that is being stratified by.

Supplementary Table 5. The prevalence, crude and multivariable adjusted relative risks and absolute differences in symptoms of depression (PHQ-9), anxiety (GAD-7) and PTSD (PC-PTSD-5) surpassing screening thresholds among individuals with and without a confirmed diagnosis of COVID-19 (*analysis limited to individuals who were tested for COVID-19*).

	No	o. (%)				
	Individuals that have been tested	Individuals that have been tested for	– cRR (95% CI)	-DD (059/ CIV ⁸	Absolute difference	Absolute difference
	for COVID-19 but not diagnosed	COVID-19 and diagnosed	CKK (33% CI)	aRR (95% CI)ª	Crude %	Adjusted ^a %
Depression	885 (19.4)	75 (22.1)	1.14 (0.92 to 1.40)	1.31 (1.06 to 1.62)	2.7	6.1
Female	712 (21.7)	56 (24.8)	1.14 (0.90 to 1.45)	1.30 (1.02 to 1.65)	3.1	6.2
Male	168 (13.2)	17 (15.2)	1.15 (0.72 to 1.82)	1.22 (0.75 to 1.97)	2.0	3.7
18-39 years	275 (37.6)	23 (27.1)	0.72 (0.50 to 1.03)	0.85 (0.58 to 1.23)	-10.5	-5.2
40-59 years	413 (17.8)	40 (22.3)	1.26 (0.94 to 1.68)	1.64 (1.23 to 2.17)	4.5	13.6
≥60 years	197 (13.1)	12 (15.8)	1.21 (0.71 to 2.07)	1.86 (1.09 to 3.18)	2.7	16.4
Anxiety	640 (13.8)	45 (13.1)	0.95 (0.72 to 1.26)	1.08 (0.81 to 1.44)	-0.7	1.1
Female	531 (15.9)	34 (14.8)	0.94 (0.68 to 1.29)	1.04 (0.75 to 1.45)	-1.1	0.6
Male	106 (8.2)	10 (8.9)	1.08 (0.58 to 2.01)	1.11 (0.60 to 2.04)	0.7	1.0
18-39 years	237 (31.3)	13 (14.9)	0.48 (0.29 to 0.80)	0.52 (0.31 to 0.89)	-16.4	-13.4
40-59 years	286 (12.1)	27 (14.7)	1.21 (0.84 to 1.75)	1.62 (1.13 to 2.31)	2.6	9.7
≥60 years	117 (7.7)	5 (6.9)	0.90 (0.38 to 2.12)	1.56 (0.66 to 3.70)	-0.8	5.1
PTSD	747 (17.8)	59 (19.5)	1.09 (0.86 to 1.39)	1.26 (0.99 to 1.60)	1.7	5.4
Female	626 (21.1)	46 (22.7)	1.08 (0.83 to 1.40)	1.19 (0.91 to 1.56)	1.6	4.5
Male	119 (9.7)	12 (12.1)	1.25 (0.71 to 2.17)	1.52 (0.86 to 2.67)	2.4	6.5
18-39 years	168 (27.6)	11 (15.3)	0.55 (0.32 to 0.97)	0.68 (0.39 to 1.18)	-12.3	-9.6
40-59 years	376 (17.4)	31 (19.3)	1.11 (0.80 to 1.54)	1.31 (0.94 to 1.83)	1.9	6.9
≥60 years	203 (14.2)	17 (24.3)	1.70 (1.11 to 2.63)	2.22 (1.46 to 3.37)	10.1	24.6

^a Adjusted for age (continuous variable), gender (male, female, or other), educational level (compulsory education, high school/trade school/other education, bachelor's degree/diploma certificate, or master's/Ph.D. degree), income (continuous variable), current smoking (yes or no), previous diagnosis of a psychiatric disorder (yes or no), number of previously diagnosed somatic diseases (0, 1, or ≥ 2), and timing of responding to the baseline questionnaire (April 24-30, May 1-7, May 8-23, or May 24-July 22). Adjustments are not made for the variable that is being stratified by.

Supplementary Table 6. Raw prevalence of flu-like symptoms during the preceding two months among individuals with and without a recent COVID-19 diagnosis.

	No.	(%)	
	Individuals not diagnosed with COVID-19 (n = 20488)	Individuals diagnosed with COVID-19 (n = 373)	P- value
No reported symptoms			
Yes	3023 (14.8)	12 (3.2)	<.001
No	17465 (85.2)	361 (96.8)	
Cough			
Never	13181 (64.3)	122 (32.7)	<.001
1-2 days	3658 (17.9)	57 (15.3)	
3-6 days	1734 (8.5)	55 (14.7)	
1-2 weeks	754 (3.7)	54 (14.5)	
Over 2 weeks	1161 (5.7)	85 (22.8)	
Fatigue and weakness			
Never	7535 (36.8)	32 (8.6)	<.001
1-2 days	6044 (29.5)	39 (10.5)	
3-6 days	3350 (16.4)	54 (14.5)	
1-2 weeks	1276 (6.2)	59 (15.8)	
Over 2 weeks	2283 (11.1)	189 (50.7)	
Fever			
Never	17362 (84.7)	127 (34.0)	<.001
1-2 days	1907 (9.3)	58 (15.5)	
3-6 days	831 (4.1)	74 (19.8)	
1-2 weeks	227 (1.1)	53 (14.2)	
Over 2 weeks	161 (0.8)	61 (16.4)	
Gastrointestinal symptoms			
Never	12589 (61.4)	162 (43.4)	<.001
1-2 days	4565 (22.3)	69 (18.5)	
3-6 days	1941 (9.5)	61 (16.4)	
1-2 weeks	585 (2.9)	42 (11.3)	
Over 2 weeks	808 (3.9)	39 (10.5)	
Headache			
Never	8583 (41.9)	73 (19.6)	<.001
1-2 days	6754 (33.0)	57 (15.3)	
3-6 days	3381 (16.5)	95 (25.5)	
1-2 weeks	816 (4.0)	62 (16.6)	
Over 2 weeks	954 (4.7)	86 (23.1)	

	No.	(%)	
	Individuals not diagnosed with COVID-19 (n = 20488)	Individuals diagnosed with COVID-19 (n = 373)	P- value
Impaired sense of taste and/or smell			
Never	19514 (95.2)	140 (37.5)	<.001
1-2 days	411 (2.0)	25 (6.7)	
3-6 days	220 (1.1)	44 (11.8)	
1-2 weeks	111 (0.5)	55 (14.7)	
Over 2 weeks	232 (1.1)	109 (29.2)	
Myalgia			
Never	12253 (59.8)	105 (28.2)	<.001
1-2 days	3512 (17.1)	54 (14.5)	
3-6 days	2072 (10.1)	72 (19.3)	
1-2 weeks	708 (3.5)	81 (21.7)	
Over 2 weeks	1943 (9.5)	61 (16.4)	
Shortness of breath			
Never	17111 (83.5)	169 (45.3)	<.001
1-2 days	1809 (8.8)	42 (11.3)	
3-6 days	775 (3.8)	55 (14.7)	
1-2 weeks	312 (1.5)	41 (11.0)	
Over 2 weeks	481 (2.3)	66 (17.7)	
Sore throat			
Never	12987 (63.4)	153 (41.0)	<.001
1-2 days	4323 (21.1)	62 (16.6)	
3-6 days	1901 (9.3)	63 (16.9)	
1-2 weeks	632 (3.1)	39 (10.5)	
Over 2 weeks	645 (3.1)	56 (15.0)	

Supplementary Table 7. Prevalence, crude and adjusted relative risks with 95% confidence intervals of flu-like symptoms lasting for 1 week or more, during the preceding two months, among individuals who tested negative for SARS-CoV-2 and those who were never tested.

	No. (%)			
Symptoms	Individuals not tested for SARS-CoV-2 (n = 15442)	Individuals tested negative for SARS-CoV-2 (n = 5046)	cRR (95% CI)	aRR (95% CI)ª
Cough	1249 (8.1)	666 (13.2)	1.60 (1.46 to 1.76)	1.59 (1.45 to 1.75)
Fatigue and weakness	2420 (15.7)	1139 (22.3)	1.45 (1.36 to 1.55)	1.37 (1.29 to 1.46)
Fever	176 (1.1)	212 (4.2)	3.71 (3.02 to 4.56)	3.49 (2.84 to 4.29)
Gastrointestinal symptoms	946 (6.1)	447 (8.9)	1.48 (1.33 to 1.66)	1.37 (1.23 to 1.53)
Headache	1134 (7.3)	636 (12.6)	1.74 (1.58 to 1.91)	1.60 (1.46 to 1.75)
Impaired sense of taste or smell	229 (1.5)	114 (2.3)	1.53 (1.21 to 1.93)	1.64 (1.30 to 2.07)
Myalgia	1881 (12.2)	770 (15.3)	1.26 (1.16 to 1.36)	1.29 (1.19 to 1.39)
Shortness of breath	503 (3.3)	290 (5.7)	1.88 (1.62 to 2.17)	1.84 (1.59 to 2.13)
Sore throat	778 (5.0)	499 (9.9)	1.98 (1.77 to 2.21)	1.91 (1.71 to 2.14)

^a Adjusted for age (continuous variable), gender (male, female, or other), educational level (compulsory education, high school/trade school/other education, bachelor's degree/diploma certificate, or master's/Ph.D. degree), income (continuous variable), current smoking (yes or no), previous diagnosis of a psychiatric disorder (yes or no), number of previously diagnosed somatic diseases (0, 1, or ≥ 2), and timing of responding to the baseline questionnaire (April 24-30, May 1-7, May 8-23, or May 24-July 22).

Supplementary Table 8. Prevalence, crude and adjusted relative risks with 95% confidence intervals of flu-like symptoms lasting for 1 week or more, during the preceding two months, among individuals with and without a confirmed diagnosis of COVID-19.

	No.	. (%)		
Symptoms	Individuals not diagnosed with COVID-19 (n = 20488)	Individuals diagnosed with COVID-19 (n = 373)	cRR (95% CI)	aRR (95% CI) ^a
Cough	1915 (9.4)	139 (37.3)	4.15 (3.60 to 4.76)	5.02 (4.35 to 5.81)
Fatigue and weakness	3559 (17.4)	248 (66.5)	3.93 (3.63 to 4.26)	4.16 (3.77 to 4.60)
Fever	388 (1.9)	114 (30.6)	16.77 (13.93 to 20.19)	19.10 (15.49 to 23.48)
Gastrointestinal symptoms	1393 (6.8)	81 (21.7)	3.29 (2.69 to 4.06)	3.49 (2.82 to 4.32)
Headache	1770 (8.6)	148 (39.7)	4.67 (4.10 to 5.37)	4.64 (3.99 to 5.39)
Impaired sense of taste or smell	343 (1.7)	164 (44.0)	27.04 (23.10 to 31.82)	32.52 (27.22 to 38.86)
Myalgia	2651 (12.9)	142 (38.1)	3.03 (2.65 to 3.49)	3.66 (3.16 to 4.23)
Shortness of breath	793 (3.9)	107 (28.7)	7.53 (6.05 to 9.03)	9.26 (7.61 to 11.25)
Sore throat	1277 (6.2)	95 (25.5)	4.17 (3.46 to 5.00)	4.58 (3.78 to 5.54)

^a Adjusted for age (continuous variable), gender (male, female, or other), educational level (compulsory education, high school/trade school/other education, bachelor's degree/diploma certificate, or master's/Ph.D. degree), income (continuous variable), current smoking (yes or no), previous diagnosis of a psychiatric disorder (yes or no), number of previously diagnosed somatic diseases (0, 1, or ≥ 2), and timing of responding to the baseline questionnaire (April 24-30, May 1-7, May 8-23, or May 24-July 22).

Supplementary Table 9. Adjusted mean symptom scores of depression, anxiety and PTSD by flu-like symptom burden in tertiles among individuals with a recent COVID-19 diagnosis, those who tested negative and those never tested for SARS-CoV-2.

	Multivariable adjusted mean value by tertile of flu-like symptoms ^a				
	Lowest tertile	Mid tertile	Highest tertile	– Beta (95% CI)	P-value
Depression					
Patients with COVID-19	5.49	7.30	10.89	0.24 (0.17 to 0.30)	<.001
Tested negative for SARS-CoV-2	6.33	9.48	10.75	0.29 (0.25 to 0.33)	<.001
Not tested for SARS- CoV-2	6.04	9.79	11.34	0.34 (0.33 to 0.36)	<.001
Anxiety	•				
Patients with COVID-19	4.31	5.29	7.02	0.12 (0.06 to 0.17)	<.001
Tested negative for SARS-CoV-2	5.06	7.16	8.02	0.19 (0.16 to 0.23)	.03
Not tested for SARS- CoV-2	4.81	7.04	8.17	0.22 (0.20 to 0.23)	<.001
PTSD					
Patients with COVID-19	1.85	2.26	2.50	0.03 (0.01 to 0.05)	<.001
Tested negative for SARS-CoV-2	1.88	2.43	2.21	0.05 (0.04 to 0.06)	.02
Not tested for SARS- CoV-2	1.82	2.31	2.59	0.06 (0.06 to 0.07)	<.001

^a Adjusted for age (continuous variable), gender (male, female, or other), educational level (compulsory education, high school/trade school/other education, bachelor's degree/diploma certificate, or master's/Ph.D. degree), income (continuous variable), current smoking (yes or no), previous diagnosis of a psychiatric disorder (yes or no), number of previously diagnosed somatic diseases (0, 1, or ≥ 2), and timing of responding to the baseline questionnaire (April 24-30, May 1-7, May 8-23, or May 24-July 22).